ContextVision (CONTX) investor relations material

Executive summary

• Q2 2026 revenue grew 23.6% year-over-year to SEK 35.3 million, with underlying growth of 1.6% after adjusting for FX and IFRS effects, indicating market stabilization and continued growth.

• Achieved a solid financial position with strong cash flow and profitability, supported by cost discipline, operational efficiency, and strengthened customer relationships, especially in China.

• Successfully passed a major OEM supplier audit, confirming compliance with IEC 62304 for medical software device lifecycle management.

• Advanced transformation toward quantitative imaging and expanded clinical development, including new protocols and a second clinical site.

• Appointment of Homer Pien to the board and recruitment of CTO Marco Voormolen, supporting strategic ambitions and a more customer-centric sales approach.

Financial highlights

• Q2 2026 revenue reached SEK 35.3 million, up 23.6% year-over-year, driven by refined revenue recognition, increased license sales, and new contracts.

• Adjusted EBITDA was SEK 15.7 million (margin 44.4%), up from SEK 5.1 million (margin 17.8%) in Q2 2025; H1 adjusted EBITDA was SEK 21.5 million (margin 33.7%).

• Adjusted EPS improved to SEK 0.16 in Q2 2026 and SEK 0.21 for H1 2026.

• Cash flow from operating activities increased to SEK 12.2 million in Q2 and SEK 14.9 million for H1; quarter-end cash position was SEK 78.5 million.

• Equity ratio at period end was 76.5%.

Outlook and guidance

• Strategic focus on long-term technology roadmap, customer-centric sales, and key partnerships, with emphasis on quantitative imaging and MASLD diagnostics.

• Stable financial position provides flexibility for future strategic initiatives and growth.

• Organizational changes and new board expertise expected to support growth and sales conversion.